Octopus has now received the approvals needed for the trial to proceed. These are from the Health Research Authority (HRA), Medicines and Healthcare products Regulatory Agency (MHRA) and the Research Ethics Committee (REC). The chosen treatments are Metformin and R/S Alpha Lipoic Acid. Further details are available via the MS Society. The next steps are now to work with ...
Trial news
MS at the Limits
Octopus featured at a recent educational event on multiple sclerosis. Prof Jeremy Chataway, the Chief Investigator for the trial, spoke to an audience of other MS professionals about the need for new treatments that slow down progressive MS, and how Octopus seeks to address that need. The talk took place at the MS at the Limits event at the end of September this year, and an ...
Octopus trial up for approval by MHRA and Research Ethics Committee
The trial team at UCL has recently submitted their application to the Medicines and Healthcare products Regulatory Agency (MHRA) and to a Research Ethics Committee. Gaining approval from both these bodies is mandatory for the trial to open to recruitment. These organisations will review the application, raise any questions or request changes that they think are needed, and in ...
Octopus team publishes article on the trial's design
Clinicians and researchers involved in Octopus have published an article in the journal Neurology. This is one of the first scientific outputs from the trial. Octopus is the first trial in MS making use of the multi-arm multistage (MAMS) platform design. The goal is to speed up the evaluation of promising drugs against progressive MS by making the trial more efficient. The a ...
